Press Releases

<< Back

CHF Solutions Expands Commercial Focus of Fluid Overloaded Patients into the Post-Cardiovascular Surgery Market

Sep 13, 2018

EDEN PRAIRIE, Minn., Sept. 13, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS), today announced that it is expanding its commercial focus into the post-cardiovascular surgery market, where, like in heart failure, patients often need treatment for fluid overload and have failed diuretic therapy. 

Surgical patients are often challenged by fluid overload post procedure due to the extra administration of fluids required during surgery.  Excess fluids, if not removed effectively, can pose a potential higher risk for morbidity, mortality, and readmissions.1,2,3,4   Given the synergies between heart failure cardiologists and cardiovascular surgeons in the treatment of heart failure patients suffering from fluid overload, the company believes expanding into the post CV surgical market is a natural next step in commercial expansion.       

“The expansion of our sales and marketing team at CHF Solutions provides us the additional resources necessary to pursue other market opportunities, and the post-cardiovascular surgery market is an excellent next foray into the market,” said John Erb, chairman and CEO of CHF Solutions. “We believe the Aquadex FlexFlow® System offers a simple form of ultrafiltration that can be prescribed by any medical specialty for the treatment of volume overload in post-surgical patients who are not responding to diuretics.  We look forward to continuing to partner with the medical community in the treatment of fluid overloaded patients and believe this initiative creates a significant market growth opportunity.”

About CHF Solutions

CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the potential of our expansion into the post-cardiovascular surgery market to be commercially successful and result in growth of the market for Aquadex Flex Flow and the ability of our expanded sales and marketing team to successfully implement the expansion to our commercial strategy.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.  Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with, and benefits from, acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made.  CHF Solutions, Inc. does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(1) Iribarne A, Chang H, Alexander JH, et al. Ann Thorac Surg. 2014 Oct; 98(4): 1274-80; (2) Holte K, Sharrock NE, Kehlet H, et al. Br J of Anaesth. 2002 Oct; 89 (4) 622-32; (3) Childs D, Cao Z, Seiberlich LE, et al. Clinicoecon Outcomes Res. 2014 Dec 15; 7:1-8; (4) Morin JF, Mistry B, Langlois Y, et al. World Journal of Cardio Surgery, 2011; 1, 18-23.

CONTACTS:

INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

chf.jpg

Source: CHF Solutions, Inc.